Notably, the majority of these genes are among the most recurrently altered drivers in DLBCL (MYD88 in 18%, CREBBP, ARID1A, and TP53 in 10%, and EZH2 in 6% of patients) [35]. Here, CREBBP is linked to diffuse large B-cell lymphoma.